(Q26992012)

J.-F. Colombel

2

1 reference

L. Peyrin-Biroulet

3

1 reference

P. Rutgeerts

4

1 reference

W. Reinisch

5

1 reference

language of work or name

1 reference

May 2013

1 reference

Alimentary Pharmacology & Therapeutics

published in

1 reference

volume

37

1 reference

issue

9

1 reference

page(s)

855-66

1 reference

Medical management of ulcerative colitis

cites work

1 reference

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

21 January 2018

1 reference

Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.

21 January 2018

1 reference

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab

21 January 2018

1 reference

A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization

21 January 2018

1 reference

Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission

21 January 2018

1 reference

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis

21 January 2018

1 reference

One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2.

21 January 2018

1 reference

Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort

21 January 2018

1 reference

Current misunderstandings in the management of ulcerative colitis

21 January 2018

1 reference

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

21 January 2018

1 reference

Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.

21 January 2018

1 reference

Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health

21 January 2018

1 reference

Long-term outcome after infliximab for refractory ulcerative colitis

21 January 2018

1 reference

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference